NFKB1 and chronic myelogenous leukemia, BCR-ABL1 positive: At last, this set of experiments confirmed that acrylamide and CML do not act in the same way on the intestinal epithelium, since neither the NF-κB nor the MAPK pathways were activated by acrylamide.